Back to Search
Start Over
BCG lowers plasma cholesterol levels and delays atherosclerotic lesion progression in mice
- Source :
- Atherosclerosis, 251, 6-14, Atherosclerosis, 251, 6-14. Elsevier Ireland Ltd, Atherosclerosis, 251, 6-14. ELSEVIER IRELAND LTD, Atherosclerosis, 251, pp. 6-14
- Publication Year :
- 2016
-
Abstract
- Contains fulltext : 172003.pdf (Publisher’s version ) (Open Access) BACKGROUND AND AIMS: Bacille-Calmette-Guerin (BCG), prepared from attenuated live Mycobacterium bovis, modulates atherosclerosis development as currently explained by immunomodulatory mechanisms. However, whether BCG is pro- or anti-atherogenic remains inconclusive as the effect of BCG on cholesterol metabolism, the main driver of atherosclerosis development, has remained underexposed in previous studies. Therefore, we aimed to elucidate the effect of BCG on cholesterol metabolism in addition to inflammation and atherosclerosis development in APOE*3-Leiden.CETP mice, a well-established model of human-like lipoprotein metabolism. METHODS: Hyperlipidemic APOE*3-Leiden.CETP mice were fed a Western-type diet containing 0.1% cholesterol and were terminated 6 weeks after a single intravenous injection with BCG (0.75 mg; 5 x 10(6) CFU). RESULTS: BCG-treated mice exhibited hepatic mycobacterial infection and hepatomegaly. The enlarged liver (+53%, p = 0.001) coincided with severe immune cell infiltration and a higher cholesterol content (+31%, p = 0.03). Moreover, BCG reduced plasma total cholesterol levels (-34%, p = 0.003), which was confined to reduced nonHDL-cholesterol levels (-36%, p = 0.002). This was due to accelerated plasma clearance of cholesterol from intravenously injected [(14)C]cholesteryl oleate-labelled VLDL-like particles (t(1/2) -41%, p = 0.002) as a result of elevated hepatic uptake (+25%, p = 0.05) as well as reduced intestinal cholestanol and plant sterol absorption (up to -37%, p = 0.003). Ultimately, BCG decreased foam cell formation of peritoneal macrophages (-18%, p = 0.02) and delayed atherosclerotic lesion progression in the aortic root of the heart. BCG tended to decrease atherosclerotic lesion area (-59%, p = 0.08) and reduced lesion severity. CONCLUSIONS: BCG reduces plasma nonHDL-cholesterol levels and delays atherosclerotic lesion formation in hyperlipidemic mice.
- Subjects :
- 0301 basic medicine
Apolipoprotein E
medicine.medical_specialty
Hypercholesterolemia
Apolipoprotein E3
Hyperlipidemias
Mice, Transgenic
Inflammation
Hepatitis
Lesion
Mice
03 medical and health sciences
chemistry.chemical_compound
Immune system
Internal medicine
Hyperlipidemia
medicine
Animals
BCG
Foam cell
business.industry
Cholesterol
Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]
medicine.disease
Atherosclerosis
Mycobacterium bovis
Phenotype
030104 developmental biology
Endocrinology
Liver
chemistry
Immune System
Immunology
BCG Vaccine
Body Composition
Disease Progression
Female
lipids (amino acids, peptides, and proteins)
medicine.symptom
business
Cardiology and Cardiovascular Medicine
BCG vaccine
Foam Cells
Subjects
Details
- ISSN :
- 00219150
- Database :
- OpenAIRE
- Journal :
- Atherosclerosis, 251, 6-14, Atherosclerosis, 251, 6-14. Elsevier Ireland Ltd, Atherosclerosis, 251, 6-14. ELSEVIER IRELAND LTD, Atherosclerosis, 251, pp. 6-14
- Accession number :
- edsair.doi.dedup.....197e5bf2b4780719720060fb13284ff2